^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ac-225 rosopatamab tetraxetan (CONV01-α)

    i
    Other names: CONV01-α, CONV 01-α, CONV 01 alpha, Actinium-225 radiolabeled J591, alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591, 225Ac-J591, Ac 225 MOAB J591, Actinium-J591
    Associations

    News

    Trials
    Company:
    Convergent Therapeutics, Dominari Holdings, Weill Cornell Medical College
    Drug class:
    Alpha radiation emitter, PSMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    23h
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Weill Medical College of Cornell University | Active, not recruiting --> Recruiting | N=37 --> 52
    Enrollment open • Enrollment change
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    22d
    Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Weill Medical College of Cornell University | Suspended --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=48 --> 20 | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    CELLSEARCH®
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    3ms
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=76 --> 37
    Enrollment closed • Enrollment change
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    7ms
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Recruiting, Weill Medical College of Cornell University | Trial completion date: Jun 2028 --> Dec 2029 | Trial primary completion date: Jun 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    8ms
    Re-treatment 225Ac-J591 for mCRPC (clinicaltrials.gov)
    P1, N=6, Completed, Weill Medical College of Cornell University | Active, not recruiting --> Completed
    Trial completion
    |
    CELLSEARCH®
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    10ms
    Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, Weill Medical College of Cornell University | Suspended --> Active, not recruiting | N=105 --> 60 | Trial completion date: Jun 2027 --> Jun 2026
    Enrollment closed • Enrollment change • Trial completion date
    |
    CELLSEARCH®
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    10ms
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=48, Suspended, Weill Medical College of Cornell University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    CELLSEARCH®
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    over1year
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Recruiting, Weill Medical College of Cornell University | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    over1year
    Re-treatment 225Ac-J591 for mCRPC (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=18 --> 6
    Enrollment closed • Enrollment change
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    over1year
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Suspended, Weill Medical College of Cornell University | Recruiting --> Suspended | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial suspension • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    over1year
    Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC (clinicaltrials.gov)
    P1/2, N=105, Suspended, Weill Medical College of Cornell University | Recruiting --> Suspended
    Trial suspension • Metastases
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    over1year
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=48, Suspended, Weill Medical College of Cornell University | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date • Metastases
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)